Sample information. (a) Skin cells from lesional (L) and nonlesional (NL) skin samples from AD (n = 2) and PSO (n = 2) patients were labeled for 12 surface makers. CD45⁺HLA-DR⁺ cells were index-sorted by flow cytometry, and expression of the panel of surface proteins was measured on individual cells. Sorted cells were also analyzed by RNA-seq to obtain RNA expression profile. (b) Gating strategy of the flow cytometry data analyzed by Smart-seq2 scRNaseq of Fig. 1. (c) RNA-based UMAP dimensional reduction of skin APC data from the four patients. The darker color dots indicate the cells in lesional skin, and the lighter color dots indicate the cells in nonlesional skin. (d) Information on skin lesion and quality control (QC) in each patient's DC and macrophages. Data from DC/macrophage, lesional/nonlesional skin, and RNA ± (QC pass or not) were overlaid onto the UMAP according to flow cytometry analysis. (e) Number of feature RNA, count RNA, and percentage of mitochondria RNA of each samples. (f) GSEA of pairwise comparisons of skin CD1c⁺CD14⁺ (CD14⁺ DC3) cells with CD1c⁺CD14⁻ cells (DC2) or CD14⁺CD88⁺ cells (MAC). Gene signatures of blood DC2s, DC3s, or CD14⁺ monocytes were used (Cytlak et al., 2020). (g) Mean expression of CD163 protein by DC2, DC3, and macrophage populations measured by CyTOF (n = 7). NES, normalized enrichment score.